152 related articles for article (PubMed ID: 9738296)
1. [Improving the specificity of PSA's in the diagnostic gray zone 4-10 ng/ml by human glandular kallikrein].
Recker F; Kwiatowski MK; Piironen T
Urologe A; 1998 Jul; 37(4):421-3. PubMed ID: 9738296
[No Abstract] [Full Text] [Related]
2. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen and other prostate cancer markers.
Stenman U; Finne P; Zhang W; Leinonen J
Urology; 2000 Dec; 56(6):893-8. PubMed ID: 11113726
[No Abstract] [Full Text] [Related]
4. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
5. Prostatic specific antigen (PSA).
Alberti C
Minerva Urol Nefrol; 1993 Jun; 45(2):83-4. PubMed ID: 7694380
[No Abstract] [Full Text] [Related]
6. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
7. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
Grond A
Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
[No Abstract] [Full Text] [Related]
8. Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer.
Wilson MJ
J Lab Clin Med; 1998 Apr; 131(4):298-9. PubMed ID: 9579381
[No Abstract] [Full Text] [Related]
9. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
[TBL] [Abstract][Full Text] [Related]
10. Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
Ulmert D; O'Brien MF; Bjartell AS; Lilja H
Nat Rev Urol; 2009 Jul; 6(7):384-91. PubMed ID: 19578355
[TBL] [Abstract][Full Text] [Related]
11. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
12. Determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases.
Kuriyama M; Abrahamsson PA; Imai K; Akimoto S; Deguchi N; Shichiri Y; Sugiyama Y; Niwa T; Inoue T
Scand J Urol Nephrol; 2001 Feb; 35(1):5-10. PubMed ID: 11291689
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
Martin AA; Clejan S
J La State Med Soc; 1994 Apr; 146(4):163-71. PubMed ID: 7516401
[No Abstract] [Full Text] [Related]
14. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer.
Sardana G; Diamandis EP
Clin Biochem; 2009 Sep; 42(13-14):1483-6. PubMed ID: 19560453
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.
Stephan C; Jung K; Diamandis EP; Rittenhouse HG; Lein M; Loening SA
Urology; 2002 Jan; 59(1):2-8. PubMed ID: 11796270
[No Abstract] [Full Text] [Related]
16. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
[TBL] [Abstract][Full Text] [Related]
17. [Significance of the PSA-concentration for the detection of prostate cancer].
Stachon A
Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
[TBL] [Abstract][Full Text] [Related]
18. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
19. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
20. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]